The effects of a plant proteinase inhibitor from Enterolobium contortisiliquum on human tumor cell lines

Biological Chemistry

Volumn 392, Issue 4, 2011, Pages 327-336

  Nakahata, Adriana Miti ^a   Mayer, Barbara ^b   Ries, Christian ^c   De Paula, Cláudia Alessandra Andrade ^a   Karow, Marisa ^c   Neth, Peter ^c   Sampaio, Misako U ^a   Jochum, Marianne ^c   Oliva, Maria Luiza V ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; Kunitz inhibitors; Matrix metalloproteinases; Mesenchymal stem cells; Plant proteinases

Indexed keywords

CHYMOTRYPSIN; GELATINASE A; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE 15; PHORBOL ESTER; PLANT PROTEINASE INHIBITOR; PLASMA KALLIKREIN; PLASMIN; PLASMINOGEN; PROTEINASE INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL STRAIN HCT116; CELL STRAIN HT29; CELL STRAIN K 562; CELL STRAIN MCF 7; CELL VIABILITY; CYTOTOXICITY; ENTEROLOBIUM CONTORTISILIQUUM; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; MEDICINAL PLANT; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL LINE;

ENTEROLOBIUM CONTORTISILIQUUM;

EID: 79955452292     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/bc.2011.031     Document Type: Article

References (82)

1. Araujo, A.P., Hansen, D., Vieira, D.F., Oliveira, C., Santana, L.A., Beltramini, L.M., Sampaio, C.A., Sampaio, M.U., and Oliva, M.L. (2005). Kunitz-type Bauhinia bauhinioides inhibitors devoid of disulfide bridges: Isolation of the cDNAs, heterologous expression and structural studies. Biol. Chem. 386, 561-568. (Pubitemid 41447577)
2. Baramova, E.N., Bajou, K., Remacle, A., L'Hoir, C., Krell, H.W., Weidle, U.H., Noel, A., and Foidart, J.M. (1997). Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 405, 157-162. (Pubitemid 27136502)
3. Barbolina, M.V. and Stack, M.S. (2008). Membrane type 1-matrix metalloproteinase: Substrate diversity in pericellular proteolysis. Semin. Cell Dev. Biol. 19, 24-33. (Pubitemid 350245611)
4. Batista, I.F., Oliva, M.L., Araujo, M.S., Sampaio, M.U., Richardson, M., Fritz, H., and Sampaio, C.A. (1996). Primary structure of a Kunitz-type trypsin inhibitor from Enterolobium contortisiliquum seeds. Phytochemistry 4, 1017-1022.
5. Bhoola, K.D., Misso, N.L., Naran, A., and Thompson, P.J. (2007). Current status of tissue kallikrein inhibitors: Importance in cancer. Curr. Opin. Investig. Drugs 8, 462-468. (Pubitemid 46868068)
6. Bidard, F.C., Pierga, J.Y., Vincent-Salomon, A., and Poupon, M.F. (2008). A 'class action' against the microenvironment: Do cancer cells cooperate in metastasis? Cancer Metastasis Rev. 27, 5-10.
7. Bjorklund, M. and Koivunen, E. (2005). Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta 1755, 37-69. (Pubitemid 40720240)
8. Braga, V. (2000). The crossroads between cell-cell adhesion and motility. Nat. Cell Biol. 2, E182-E184.
9. Brew, K. and Nagase, H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim. Biophys. Acta 1803, 55-71.
10. Chao, J.C. and Chu, C.C. (2004). Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World J. Gastroenterol. 10, 37-41. (Pubitemid 38071974)
11. Dani, R., Godoy, P., Jardim, M.V., and Raso, P. (1963). In vitro and in vivo study of a trypsin inhibitor in acute pancreatitis: Experimental study and a report of its use in human case. Hospital (Rio J.) 64, 635-649.
12. de Oliveira, C., Santana, L.A., Carmona, A.K., Cezari, M.H., Sampaio, M.U., Sampaio, C.A., and Oliva, M.L. (2001). Structure of cruzipain/cruzain inhibitors isolated from Bauhinia bauhinioides seeds. Biol. Chem. 382, 847-852. (Pubitemid 32631724)
13. DeClerck, Y.A., Mercurio, A.M., Stack, M.S., Chapman, H.A., Zutter, M.M., Muschel, R.J., Raz, A., Matrisian, L.M., Sloane, B.F., Noel, A., et al. (2004). Proteases, extracellular matrix, and cancer: A workshop of the path B study section. Am. J. Pathol. 164, 1131-1139. (Pubitemid 38387779)
14. Diasio, R.B. and Johnson, M.R. (2000). The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5- fluorouracil. Pharmacology 61, 199-203.
15. Duffy, M.J. and Duggan, C. (2004). The urokinase plasminogen activator system: A rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37, 541-548. (Pubitemid 38845017)
16. Duffy, M.J., McGowan, P.M., and Gallagher, W.M. (2008). Cancer invasion and metastasis: Changing views. J. Pathol. 214, 283-293. (Pubitemid 351212383)
17. Egeblad, M. and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174. (Pubitemid 37328786)
18. Fashena, S.J. and Thomas, S.M. (2000). Signalling by adhesion receptors. Nat. Cell Biol. 2, E225-E229.
19. Fingleton, B. (2007). Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 13, 333-346. (Pubitemid 46085282)
20. Foekens, J.A., Ries, C., Look, M.P., Gippner-Steppert, C., Klijn, J.G., and Jochum, M. (2003a). Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br. J. Cancer 88, 1084-1090. (Pubitemid 36560780)
21. Foekens, J.A., Ries, C., Look, M.P., Gippner-Steppert, C., Klijn, J.G., and Jochum, M. (2003b). The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res. 63, 337-341. (Pubitemid 36152490)
22. Fritz, H. and Wunderer, G. (1983). Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 33, 479-494. (Pubitemid 13161964)
23. Germanov, E., Berman, J.N., and Guernsey, D.L. (2006). Current and future approaches for the therapeutic targeting of metastasis. Int. J. Mol. Med. 18, 1025-1036.
24. Gocheva, V. and Joyce, J.A. (2007). Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6, 60-64. (Pubitemid 46173882)
25. Golubkov, V.S., Cieplak, P., Chekanov, A.V., Ratnikov, B.I., Aleshin, A.E., Golubkova, N.V., Postnova, T.I., Radichev, I.A., Rozanov, D.V., Zhu, W., et al. (2010). Internal cleavages of the autoinhibitory prodomain are required for membrane type 1 matrix metalloproteinase activation, although furin cleavage alone generates inactive proteinase. J. Biol. Chem. 285, 27726-27736.
26. Han, Y.P., Nien, Y.D., and Garner, W.L. (2002). Tumor necrosis factor-a-induced proteolytic activation of pro-matrix metalloproteinase- 9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase. J. Biol. Chem. 277, 27319-27327. (Pubitemid 34951751)
27. Hildenbrand, R., Gandhari, M., Stroebel, P., Marx, A., Allgayer, H., and Arens, N. (2008). The urokinase-system - role of cell proliferation and apoptosis. Histol. Histopathol. 23, 227-236.
28. Hoekstra, R., Eskens, F.A., and Verweij, J. (2001). Matrix metalloproteinase inhibitors: Current developments and future perspectives. Oncologist 6, 415-427. (Pubitemid 33022212)
29. Hoelters, J., Ciccarella, M., Drechsel, M., Geissler, C., Gulkan, H., Bocker, W., Schieker, M., Jochum, M., and Neth, P. (2005). Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells. J. Gene Med. 7, 718-728. (Pubitemid 40872858)
30. Itoh, Y. and Seiki, M. (2006). MT1-MMP: A potent modifier of pericellular microenvironment. J. Cell. Physiol. 206, 1-8. (Pubitemid 41740711)
31. Janicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C.G., Selbmann, H.K., Graeff, H., and Schmitt, M. (2001). Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 93, 913-920. (Pubitemid 32624648)
32. Jedeszko, C. and Sloane, B.F. (2004). Cysteine cathepsins in human cancer. Biol. Chem. 385, 1017-1027. (Pubitemid 39600309)
33. Kallakury, B.V., Karikehalli, S., Haholu, A., Sheehan, C.E., Azumi, N., and Ross, J.S. (2001). Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin. Cancer Res. 7, 3113-3119. (Pubitemid 32963832)
34. Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141, 52-67.
35. Koblinski, J.E., Ahram, M., and Sloane, B.F. (2000). Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135. (Pubitemid 30089760)
36. Lah, T.T., Duran Alonso, M.B., and Van Noorden, C.J. (2006). Antiprotease therapy in cancer: Hot or not? Expert Opin. Biol. Ther. 6, 257-279. (Pubitemid 43344745)
37. Lazar, M., Sullivan, J., Chipitsyna, G., Gong, Q., Ng, C.Y., Salem, A.F., Aziz, T., Witkiewicz, A., Denhardt, D.T., Yeo, C.J., et al. (2010). Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells. J. Gastrointest. Surg. 14, 1566-1577.
38. Leipner, J. and Saller, R. (2000). Systemic enzyme therapy in oncology: Effect and mode of action. Drugs 59, 769-780. (Pubitemid 30232319)
39. Liotta, L.A. and Clair, T. (2000). Cancer. Checkpoint for invasion. Nature 405, 287-288.
40. Liu, D., Nakano, J., Ishikawa, S., Yokomise, H., Ueno, M., Kadota, K., Urushihara, M., and Huang, C.L. (2007). Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58, 384-391. (Pubitemid 350051513)
41. Lopez-Otin, C. and Matrisian, L.M. (2007). Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808. (Pubitemid 47463671)
42. Lukashev, M.E. and Werb, Z. (1998). ECM signalling: Orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8, 437-441. (Pubitemid 28529716)
43. Macedo, M.L., Durigan, R.A., da Silva, D.S., Marangoni, S., Freire, M.G., and Parra, J.R. (2010). Adenanthera pavonina trypsin inhibitor retard growth of Anagasta kuehniella (Lepidoptera: Pyralidae). Arch. Insect Biochem. Physiol. 73, 213-231.
44. Martin, M.D. and Matrisian, L.M. (2007). The other side of MMPs: Protective roles in tumor progression. Cancer Metastasis Rev. 26, 717-724. (Pubitemid 350115119)
45. Miyasaka, M. (1995). Cancer metastasis and adhesion molecules. Clin. Orthop. Relat. Res. 312, 10-18.
46. Moll, U.M., Youngleib, G.L., Rosinski, K.B., and Quigley, J.P. (1990). Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: Isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res. 50, 6162-6170. (Pubitemid 20323668)
47. Morrison, J.F. (1982). The slow-binding and slow, tight-binding inhibition of enzyme-catalysed reactions. Trends Biochem. Sci. 7, 102-105.
48. Murphy, G. and Crabbe, T. (1995). Gelatinases A and B. Methods Enzymol. 248, 470-484.
49. Nagase, H. and Woessner, J.F. Jr. (1999). Matrix metalloproteinases. J. Biol. Chem. 274, 21491-21494.
50. Nagase, H., Visse, R., and Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562-573. (Pubitemid 43139720)
51. Nakahata, A.M., Bueno, N.R., Rocha, H.A., Franco, C.R., Chammas, R., Nakaie, C.R., Jasiulionis, M.G., Nader, H.B., Santana, L.A., Sampaio, M.U., et al. (2006). Structural and inhibitory properties of a plant proteinase inhibitor containing the RGD motif. Int. J. Biol. Macromol. 40, 22-29. (Pubitemid 44816370)
52. Nguyen, T.H. (2004). Mechanisms of metastasis. Clin. Dermatol. 22, 209-216. (Pubitemid 38950747)
53. Noel, A., Jost, M., and Maquoi, E. (2008). Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol. 19, 52-60. (Pubitemid 350235981)
54. Nozawa, F., Hirota, M., Okabe, A., Shibata, M., Iwamura, T., Haga, Y., and Ogawa, M. (2000). Elastase activity enhances the adhesion of neutrophil and cancer cells to vascular endothelial cells. J. Surg. Res. 94, 153-158.
55. Ohkoshi, M. and Sasaki, Y. (2005). Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan). In Vivo 19, 133-136. (Pubitemid 40450387)
56. Oliva, M.L. and Sampaio, U.M. (2008). Bauhinia Kunitz-type proteinase inhibitors: Structural characteristics and biological properties. Biol. Chem. 389, 1007-1013.
57. Oliva, M.L. and Sampaio, M.U. (2009). Action of plant proteinase inhibitors on enzymes of physiopathological importance. An. Acad. Bras. Cienc. 81, 615-621.
58. Oliva, M.L., Mendes, C.R., Santomauro-Vaz, E.M., Juliano, M.A., Mentele, R., Auerswald, E.A., Sampaio, M.U., and Sampaio, C.A. (2001). Bauhinia bauhinioides plasma kallikrein inhibitor: Interaction with synthetic peptides and fluorogenic peptide substrates related to the reactive site sequence. Curr. Med. Chem. 8, 977-984. (Pubitemid 32633556)
59. Parise, L.V., Lee, J., and Juliano, R.L. (2000). New aspects of integrin signaling in cancer. Semin. Cancer Biol. 10, 407-414. (Pubitemid 32181911)
60. Park, C.C., Bissell, M.J., and Barcellos-Hoff, M.H. (2000). The influence of the microenvironment on the malignant phenotype. Mol. Med. Today 6, 324-329. (Pubitemid 30619340)
61. Prasad, E.R., Dutta-Gupta, A., and Padmasree, K. (2010). Purification and characterization of a Bowman-Birk proteinase inhibitor from the seeds of black gram (Vigna mungo). Phytochemistry 71, 363-372.
62. Ramos-DeSimone, N., Hahn-Dantona, E., Sipley, J., Nagase, H., French, D.L., and Quigley, J.P. (1999). Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin- 1 cascade enhances tumor cell invasion. J. Biol. Chem. 274, 13066-13076.
63. Roghi, C., Jones, L., Gratian, M., English, W.R., and Murphy, G. (2010). Golgi reassembly stacking protein 55 interacts with membrane-type (MT) 1-matrix metalloprotease (MMP) and furin and plays a role in the activation of the MT1-MMP zymogen. FEBS J. 277, 3158-3175.
64. Roy, S. and Dutta, S.K. (2009). Genomic and cDNA cloning, expression, purification, and characterization of chymotrypsintrypsin inhibitor from winged bean seeds. Biosci. Biotechnol. Biochem. 73, 2671-2676.
65. Sato, T., Takahashi, S., Mizumoto, T., Harao, M., Akizuki, M., Takasugi, M., Fukutomi, T., and Yamashita, J. (2006). Neutrophil elastase and cancer. Surg. Oncol. 15, 217-222. (Pubitemid 46771195)
66. Seiki, M. (2003). Membrane-type 1 matrix metalloproteinase: A key enzyme for tumor invasion. Cancer Lett. 194, 1-11. (Pubitemid 36428879)
67. Shamamian, P., Schwartz, J.D., Pocock, B.J., Monea, S., Whiting, D., Marcus, S.G., and Mignatti, P. (2001). Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: A role for inflammatory cells in tumor invasion and angiogenesis. J. Cell. Physiol. 189, 197-206. (Pubitemid 32946031)
68. Skrzydlewska, E., Sulkowska, M., Koda, M., and Sulkowski, S. (2005). Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J. Gastroenterol. 11, 1251-1266. (Pubitemid 40425906)
69. Sloane, B.F., Sameni, M., Podgorski, I., Cavallo-Medved, D., and Moin, K. (2006). Functional imaging of tumor proteolysis. Annu. Rev. Pharmacol. Toxicol. 46, 301-315. (Pubitemid 43271192)
70. Sorsa, T., Salo, T., Koivunen, E., Tyynela, J., Konttinen, Y.T., Bergmann, U., Tuuttila, A., Niemi, E., Teronen, O., Heikkila, P., et al. (1997). Activation of type IV procollagenases by human tumor-associated trypsin-2. J. Biol. Chem. 272, 21067-21074. (Pubitemid 27373964)
71. Stanton, H., Gavrilovic, J., Atkinson, S.J., d'Ortho, M.P., Yamada, K.M., Zardi, L., and Murphy, G. (1998). The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J. Cell Sci. 111, 2789-2798. (Pubitemid 28479202)
72. Stearns, M. and Stearns, M.E. (1996). Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol. Res. 8, 69-75. (Pubitemid 26134926)
73. Sternlicht, M.D. and Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516. (Pubitemid 33096184)
74. Sumikawa, J.T., Nakahata, A.M., Fritz, H., Mentele, R., Sampaio, M.U., and Oliva, M.L. (2006). A Kunitz-type glycosylated elastase inhibitor with one disulfide bridge. Planta Med. 72, 393-397.
75. Sun, Z. and Yang, P. (2004). Role of imbalance between neutrophil elastase and a1-antitrypsin in cancer development and progression. Lancet Oncol. 5, 182-190. (Pubitemid 38262851)
76. Turk, B. (2006). Targeting proteases: Successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799. (Pubitemid 44323703)
77. Turpeenniemi-Hujanen, T. (2005). Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87, 287-297. (Pubitemid 40387607)
78. Werb, Z. (1997). ECM and cell surface proteolysis: Regulating cellular ecology. Cell 91, 439-442. (Pubitemid 27508232)
79. Will, H., Atkinson, S.J., Butler, G.S., Smith, B., and Murphy, G. (1996). The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem. 271, 17119-17123. (Pubitemid 26244261)
80. Wolf, K. and Friedl, P. (2006). Molecular mechanisms of cancer cell invasion and plasticity. Br. J. Dermatol. 154 (Suppl. 1), 11-15.
81. Woodhouse, E.C., Chuaqui, R.F., and Liotta, L.A. (1997). General mechanisms of metastasis. Cancer 80 (Suppl. 8), 1529-1537. (Pubitemid 27444024)
82. Zucker, S., Pei, D., Cao, J., and Lopez-Otin, C. (2003). Membrane type-matrix metalloproteinases (MT-MMP). Curr. Top. Dev. Biol. 54, 1-74. (Pubitemid 137639464)